Ticker >

Suven Life Sciences share price

Suven Life Sciences Ltd.

NSE: SUVEN BSE: 530239 SECTOR: Pharmaceuticals & Drugs  73k   134   25

101.70
+1.75 (1.75%)
NSE: Today, 01:54 PM

Price Summary

Today's High

₹ 101.9

Today's Low

₹ 100

52 Week High

₹ 129

52 Week Low

₹ 47.5

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

2217.81 Cr.

Enterprise Value

2043.85 Cr.

No. of Shares

21.81 Cr.

P/E

0

P/B

2.61

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  38.92

CASH

173.96 Cr.

DEBT

0 Cr.

Promoter Holding

69.57 %

EPS (TTM)

₹  -0.33

Sales Growth

14.31%

ROE

-3.03 %

ROCE

-2.95%

Profit Growth

44.47 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year14.31%
3 Year-2.07%
5 Year-53.54%

Profit Growth

1 Year44.47%
3 Year-18.74%
5 Year-166.19%

ROE%

1 Year-3.03%
3 Year-5.89%
5 Year-2.99%

ROCE %

1 Year-2.95%
3 Year-5.96%
5 Year-2.86%

Debt/Equity

0

Price to Cash Flow

-219.86

Interest Cover Ratio

-37.6170376055257

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 69.57 0
Sep 2023 69.57 0
Jun 2023 69.57 0
Mar 2023 69.57 0
Dec 2022 69.57 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 0.4843 Cr.
  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 28.3781353403451 days.
  • Company has a healthy liquidity position with current ratio of 3.40493185253816.
  • The company has a high promoter holding of 69.57%.

 Limitations

  • The company has shown a poor profit growth of -18.7415549323434% for the Past 3 years.
  • The company has shown a poor revenue growth of -2.06696302335596% for the Past 3 years.
  • Company has a poor ROE of -5.88906186045951% over the past 3 years.
  • Company has a poor ROCE of -5.95622331971949% over the past 3 years
  • Company has negative cash flow from operations of -10.0872.
  • The company has a low EBITDA margin of -192.785867287581% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 3 2.61 3.8 3.06 2.45
Total Expenditure 10.11 8.74 10.59 11.14 11.65
Operating Profit -7.1 -6.13 -6.8 -8.08 -9.2
Other Income 2.21 5.6 5.64 5.14 6.07
Interest 0.06 0.05 0.05 0.04 0.04
Depreciation 1.67 1.67 1.67 1.73 1.6
Exceptional Items 0 0 0 7.46 0
Profit Before Tax -6.63 -2.25 -2.87 2.76 -4.77
Tax 0 0 0 0 0
Profit After Tax -6.63 -2.25 -2.87 2.76 -4.77
Adjusted EPS (Rs) -0.3 -0.1 -0.13 0.13 -0.22

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 285.67 14.41 13.48 11.84 13.54
Total Expenditure 233.56 49.68 43.93 48.37 41.05
Operating Profit 52.11 -35.26 -30.45 -36.53 -27.51
Other Income 27.25 14.04 7.75 1.6 8.45
Interest 1.9 0.54 0.91 0.64 0.52
Depreciation 14.2 4.17 4.35 4.39 6.54
Exceptional Items 0 0 0 3.72 6
Profit Before Tax 63.25 -25.94 -27.95 -36.25 -20.13
Tax 24.06 -12.18 -5.32 0 0
Net Profit 39.19 -13.75 -22.63 -36.25 -20.13
Adjusted EPS (Rs.) 2.84 -1 -1.64 -2.3 -0.92

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 12.73 12.73 12.73 14.54 21.81
Total Reserves 388.99 374.95 388.93 461.44 831.64
Borrowings 1.78 1.08 0.39 0 0
Other N/C liabilities 22.73 10.99 4.11 3.57 2.46
Current liabilities 130.51 103.53 103.13 100.7 98.43
Total Liabilities 556.74 503.28 509.28 580.25 954.34
Assets
Net Block 22.35 24.69 20.96 37.56 37.21
Capital WIP 0.02 0 4.77 3.55 0
Intangible WIP 0 0 0 0 0
Investments 136.36 241.81 295.03 380.69 481.86
Loans & Advances 0 91.25 0 0.33 0.11
Other N/C Assets 0 0 0 0 100
Current Assets 398.01 145.52 188.52 158.12 335.16
Total Assets 556.74 503.28 509.28 580.25 954.34
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 63.25 -25.94 -27.96 -36.25 -20.13
Adjustment -4.88 -9.26 -2.7 -1.09 4.74
Changes in Assets & Liabilities -55.46 -7.17 -4.88 1.24 6.4
Tax Paid -14.92 -2.78 -1.15 -0.52 -1.1
Operating Cash Flow -12.01 -45.15 -36.68 -36.62 -10.09
Investing Cash Flow -3.52 42.03 2.41 -107.46 -361.66
Financing Cash Flow 4.55 3.81 34.86 145.69 395.54
Net Cash Flow -10.98 0.69 0.58 1.61 23.79

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 69.57 69.57 69.57 69.57 69.57
jasti property and equity... - - 69.56 69.56 69.56
jasti property and equity... - 69.56 - - -
jasti property and equity... 69.56 - - - -
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 30.43 30.43 30.43 30.43 30.43
investor education and pr... 0.10 0.10 - - 0.11
rambabu chirumamilla 1.38 - 1.38 1.38 1.38
investor education and pr... - - 0.11 0.11 -
sattva organisers llp 1.02 1.02 1.02 - -

Annual Reports

Ratings & Research Reports

Company Presentations

  • PresentationQ2FY19 9 Jan 2020

Company News

Suven Pharmaceuticals to merge Cohance with itself1 Mar 2024, 11:30AM Suven Life Sciences - Quaterly Results30 Jan 2024, 12:57PM Suven Life Sciences - Quaterly Results30 Jan 2024, 12:57PM Suven Life Sciences - Quaterly Results30 Jan 2024, 12:57PM Suven Pharmaceuticals informs about board meeting29 Jan 2024, 5:23PM Suven Pharmaceuticals informs about BRSR23 Nov 2023, 4:15PM Suven Life Sciences - Quaterly Results4 Nov 2023, 12:41PM Suven Life Sciences - Quaterly Results4 Nov 2023, 12:41PM Suven Life Sciences - Quaterly Results4 Nov 2023, 12:41PM Suven Pharmaceuticals informs about disclosure26 Sep 2023, 5:07PM Suven Life Sciences informs about loss of share certificate16 Sep 2023, 3:58PM CCEA approves foreign investment of up to Rs 9589 crore in Suven Pharmaceuticals 14 Sep 2023, 4:37PM Suven Life Sciences informs about monitoring agency report9 Aug 2023, 4:34PM Suven Life Sciences - Quaterly Results8 Aug 2023, 1:02PM Suven Life Sciences - Quaterly Results8 Aug 2023, 1:02PM Suven Life Sciences - Quaterly Results8 Aug 2023, 1:02PM Suven Life Sciences informs about newspaper publication10 May 2023, 1:09PM Suven Life Sciences - Quaterly Results9 May 2023, 1:14PM Suven Life Sciences - Quaterly Results9 May 2023, 1:14PM Suven Life Sciences - Quaterly Results9 May 2023, 1:14PM Suven Life Sciences informs about loss of share certificate6 Mar 2023, 5:00PM Suven Life Sciences informs about monitoring agency report9 Feb 2023, 4:55PM Suven Life Sciences informs about disclosure2 Feb 2023, 4:41PM Suven Life Sciences - Quaterly Results2 Feb 2023, 1:46PM Suven Life Sciences - Quaterly Results2 Feb 2023, 1:46PM Suven Life Sciences - Quaterly Results2 Feb 2023, 1:46PM Suven Life Sciences informs about compliances-certificate6 Jan 2023, 1:01PM Suven Life Sciences randomizes first patient in phase-3 global clinical trial of Masupirdine 17 Nov 2022, 11:59AM Suven Life Sciences - Quaterly Results10 Nov 2022, 5:14PM Suven Life Sciences - Quaterly Results10 Nov 2022, 5:14PM Suven Life Sciences informs about compliance certificate12 Oct 2022, 12:11PM Suven Life Sciences informs about closure of trading window 30 Sep 2022, 4:44PM Suven Life Sciences - Quaterly Results26 Jul 2022, 1:26PM Suven Life Sciences - Quaterly Results26 Jul 2022, 1:26PM Suven Life Sciences - Quaterly Results26 Jul 2022, 1:26PM Suven Life Sciences informs about AGM11 Jul 2022, 3:33PM Suven Life Sciences gets nod to raise Rs 400 crore on rights basis24 Jun 2022, 2:21PM Suven Life Sciences informs about loss of share certificate16 Jun 2022, 5:00PM Suven Life Sciences - Quaterly Results7 May 2022, 1:25PM Suven Life Sciences - Quaterly Results7 May 2022, 1:25PM Suven Life Sciences - Quaterly Results7 May 2022, 1:25PM Suven Life Sciences informs about clarification on increase in volume1 Apr 2022, 2:56PM Suven Life Sciences informs about allotment of equity shares28 Mar 2022, 4:52PM Suven Life Sciences informs about outcome of board meeting 28 Mar 2022, 1:57PM Suven Life Sciences informs about allotment of equity shares28 Mar 2022, 1:52PM Suven Life Sciences - Quaterly Results31 Jan 2022, 12:40PM Suven Life Sciences - Quaterly Results31 Jan 2022, 12:40PM Suven Life Sciences informs about board meeting24 Jan 2022, 2:51PM Suven Life Sciences informs about compliance certificate4 Jan 2022, 4:40PM Suven Life Sciences - Quaterly Results25 Oct 2021, 1:07PM

Suven Life Sciences Stock Price Analysis and Quick Research Report. Is Suven Life Sciences an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Suven Life Sciences and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Suven Life Sciences cash from the operating activity was Rs -10.0872 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Suven Life Sciences has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Suven Life Sciences , the EPS growth was 59.8258977149075 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Suven Life Sciences has OPM of -203.201813991964 % which is a bad sign for profitability.
     
  • ROE: Suven Life Sciences have a poor ROE of -3.02796298360686 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Suven Life Sciences is Rs 100.5. One can use valuation calculators of ticker to know if Suven Life Sciences share price is undervalued or overvalued.
Last Updated on:
Brief about Suven Life Sciences
X